Designer Drugs: Hearing Before the Subcommittee on Crime of the Committee on the Judiciary, House of Representatives, Ninety-ninth Congress, First Session, on H.R. 2014, H.R. 2977, H.R. 3936, and S. 1437, May 1, 1986U.S. Government Printing Office, 1986 - 199 sider |
Inni boken
Resultat 1-5 av 41
Side 10
... question that we are talking about . [ Video tape presentation : " The Walking Death . " ] Mr. HUGHES . I want to thank the gentleman from California for an excellent presentation . Congressman Charley Rangel is involved in a markup and ...
... question that we are talking about . [ Video tape presentation : " The Walking Death . " ] Mr. HUGHES . I want to thank the gentleman from California for an excellent presentation . Congressman Charley Rangel is involved in a markup and ...
Side 15
... substances and what action including legislation DEA would recommend control the problem . I will be pleased to answer any questions Members of Subcommittee may have . to the Mr. HUGHES . I would like to welcome here this 15.
... substances and what action including legislation DEA would recommend control the problem . I will be pleased to answer any questions Members of Subcommittee may have . to the Mr. HUGHES . I would like to welcome here this 15.
Side 21
... question that we need a strategy that includes education , demand reduction and treatment . It is disgrace- ful that in my own State alone , New Jersey , we have 10,000 hard core addicts walking around that want help , that need help ...
... question that we need a strategy that includes education , demand reduction and treatment . It is disgrace- ful that in my own State alone , New Jersey , we have 10,000 hard core addicts walking around that want help , that need help ...
Side 22
... question , Lawton , to you about what did or didn't take place in the Senate hearings . As I under- stand , we are going to have some complaints from people in re- search that the broader laws that you proposed and that are before us ...
... question , Lawton , to you about what did or didn't take place in the Senate hearings . As I under- stand , we are going to have some complaints from people in re- search that the broader laws that you proposed and that are before us ...
Side 23
... question because Mr. Lungren's bill is the Senate bill . My bill goes a little further ; it also deals with the Attorney Gener- al and asking that agency for a study of the precursor chemicals . I think it is not enough just to in fact ...
... question because Mr. Lungren's bill is the Senate bill . My bill goes a little further ; it also deals with the Attorney Gener- al and asking that agency for a study of the precursor chemicals . I think it is not enough just to in fact ...
Andre utgaver - Vis alle
Vanlige uttrykk og setninger
amended amphetamine appropriate approval Attorney bill California Chairman chemical structure chemists clandestine laboratories Committee compounds conducted CONGRESS THE LIBRARY controlled substance analogs Controlled Substances Act Cosmetic Act criminal Department of Health designer drug manufacture designer drug problem drug abuse Drug Enforcement Drug Enforcement Administration drug or substance effect emergency scheduling exemption Federal Food fentanyl analogs fetus Florida Food and Drug GRINSPOON HAWKS Health and Human heroin HUGHES human consumption Human Services human subjects illegal illicit drug individuals informed consent Institutional Review Board intended for human intent to distribute investigational law enforcement legislation legitimate research LIBRARY OF CONGRESS LUNGREN MCCOLLUM MDMA meperidine MPPP MPTP NIDA paragraph Parkinson's disease potential procedures produce programs public health regulations research involving Secretary of Health Senator CHILES specific statement studies subpart substance in Schedules substantially similar synthetic Thank therapeutic tion Tocus toxicity trolled substance
Populære avsnitt
Side 39 - I would be pleased to respond to any questions you or members of the committee may have.
Side 178 - Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.
Side 178 - Private information includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and which the individual can reasonably expect will not be made public (for example, a medical record). Private information must be individually identifiable (ie, the identity of the subject is or may readily be ascertained by the investigator or...
Side 33 - No person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) is effective with respect to such drug.
Side 178 - ... for determining which projects require review more often than annually and which projects need verification from sources other than the investigators that no material changes have occurred since previous IRB review...
Side 177 - Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available, or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
Side 179 - Except when an expedited review procedure is used (see § 46. 1 10), review proposed research at convened meetings at which a majority of the members of the IRB are present, including at least one member whose primary concerns are in nonscientific areas. In order for the research to be approved, it shall receive the approval of a majority of those members present at the meeting.
Side 185 - The purpose of the activity is to meet the health needs of the mother and the fetus will be placed at risk only to the minimum extent necessary to meet such needs, or (2) the risk to the fetus is minimal.
Side 178 - A statement of principles governing the institution in the discharge of its responsibilities for protecting the rights and welfare of human subjects of research conducted at or sponsored by the institution, regardless of whether the research is subject to federal regulation.
Side 188 - The risk represents a minor increase over minimal risk; (b) The intervention or procedure presents experiences to subjects that are reasonably commensurate with those inherent in their actual or expected medical, dental, psychological, social, or educational situations; 45 CFR Subtitle A (10-1-93 Edition) (c) The intervention or procedure is likely to yield generalizable knowledge about the subjects...